Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Apr 25, 2016	Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis SOLANA BEACH, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has successfully completed patient enrollment in its pivotal Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms	View HTML Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 17.9 KB
Toggle Summary May 03, 2016	Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001 SOLANA BEACH, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK) today announced that it expects to provide top line data results from its pivotal Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter of	View HTML Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001 15.6 KB
Toggle Summary May 05, 2016	Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2016 Financial Results SOLANA BEACH, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter 2016 on Wednesday, May 11, 2016, after	View HTML Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2016 Financial Results 15.6 KB
Toggle Summary May 11, 2016	Evoke Pharma Reports First Quarter 2016 Results SOLANA BEACH, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2016.	View HTML Evoke Pharma Reports First Quarter 2016 Results 25 KB
Toggle Summary May 19, 2016	Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001 SOLANA BEACH, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has signed an exclusive commercial supply agreement with COSMA S.p.A. for the active pharmaceutical ingredient (API) in its product candidate EVK-001.	View HTML Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001 16.1 KB
Toggle Summary May 24, 2016	Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 Further Safety of EVK-001 Demonstrated with TQT Results	View HTML Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 16.5 KB
Toggle Summary Jun 01, 2016	Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 205 subjects complete the study	View HTML Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 16.9 KB
Toggle Summary Jul 07, 2016	Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement SOLANA BEACH, Calif. , July 07, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has entered into a master service agreement with inVentiv Commercial Services LLC ("inVentiv") in connection with Evoke's preparation for commercial activities for EVK-001, its lead	View HTML Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement 15.9 KB
Toggle Summary Jul 18, 2016	Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial SOLANA BEACH, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced topline results from its Phase 3 clinical trial of EVK-001 in female patients with symptomatic	View HTML Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial 18.1 KB
Toggle Summary Jul 20, 2016	Evoke Pharma Announces $4.5 Million At-The-Market Offering SOLANA BEACH, Calif., July 20, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for an	View HTML Evoke Pharma Announces $4.5 Million At-The-Market Offering 15.4 KB